CLINICAL TRIAL CENTER MAASTRICHT

Their core work

Clinical Trial Center Maastricht (CTCM) is a private clinical trial management organization that provides trial execution infrastructure for academic and pharmaceutical research studies. Their core function is running randomized controlled trials — from patient recruitment and protocol adherence to data collection — serving as an operational partner embedded within large research consortia. They have contributed to EU H2020 trials in two distinct disease areas: cancer immunotherapy combined with stereotactic ablative radiotherapy, and diabetic cardiovascular disease. As a standalone trial center rather than a hospital department or academic unit, they offer focused clinical research operations that larger institutions often cannot deliver with the same agility.

What they specialise in

How they've shifted over time

CTCM's earliest H2020 involvement (from 2017) was in oncology — a Phase II trial combining immunotherapy (L19-IL2) with stereotactic ablative radiotherapy for lung and metastatic cancer, a clinically ambitious dual-modality approach. By 2019 they had joined a cardiometabolic study on diabetic cardiomyopathy that incorporates omics, systems biology, and disease modeling. This shift from single-disease oncology to a molecularly complex cardiovascular study suggests a deliberate broadening of their clinical trial portfolio toward data-intensive, multi-endpoint research designs.

CTCM is expanding from oncology into cardiovascular and metabolic disease, with their most recent project incorporating omics and systems biology — signaling growing appetite for molecularly stratified, data-rich trial designs.

How they like to work

CTCM participates exclusively as a third party in EU projects, functioning as a clinical trial execution unit rather than a scientific lead or coordinator. Both projects placed them inside large RIA consortia — 49 unique partners across 10 countries from just two engagements — indicating they are embedded in well-resourced, multi-national collaborations. Their role is to provide operational clinical infrastructure and execution capacity, not to drive the research agenda or manage the consortium.

CTCM has engaged with 49 unique partners across 10 countries through only two projects, reflecting their integration into large EU research consortia rather than a broad independent network. Their geographic footprint is European, anchored in the Dutch clinical research ecosystem around Maastricht.

What sets them apart

As a standalone private clinical trial center rather than a hospital department or large CRO, CTCM occupies a focused niche: dedicated trial management expertise without the institutional overhead of a university hospital. Their cross-therapeutic experience — spanning oncology and cardiovascular disease — makes them a versatile clinical execution partner for consortium leaders needing a Netherlands-based trial site. For EU research consortia requiring GCP-compliant randomized trial operations in a compact, professionally specialized setting, CTCM offers a differentiated alternative to academic clinical units.

Highlights from their portfolio

• IMMUNOSABR
  A randomized Phase II proof-of-concept trial (2017–2024) combining L19-IL2 immunotherapy with stereotactic ablative radiotherapy — a clinically ambitious dual-modality approach for metastatic lung cancer that ran for seven years.
• CARDIATEAM
  A 2019–2026 study on diabetic cardiomyopathy integrating omics and systems biology for disease modeling, reflecting CTCM's move into molecularly complex, data-intensive cardiovascular research.